What are your top takeaways in Melanoma from ASCO 2022?
What were your “top 3” presentations/studies coming out of the meeting this year and how will it impact your own clinical practice?
1 Answer
Mednet MemberInvited Expert
Medical Oncology · The Ohio State University Comprehensive Cancer Center/James Cancer Hospital and Solove Research Institute
Answered on
1. Melanoma oral abstract session #3: Abstract 9502 Neoadjuvant PD-1 blockade in patients with resectable desmoplastic melanoma (SWOG 1512)
Desmoplastic melanoma is a rare subtype of melanoma that frequently occurs in the head/neck area and is very difficult to completely resect due to its invasiveness and frequent perineural invasion. It has high tumor mutation burden and is responsive to immune checkpoint therapy. In this study, 29 patients with resectable desmoplastic melanoma underwent 3 cycl...
Join for free or sign in to see the full answer